[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614864":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":25,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":25,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":25,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":25},{"fullName":5,"class":6},"Singapore General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Glycine","ACTIVE_COMPARATOR","9g per day of glycine in capsules",[13],"Dietary Supplement: Glycine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Microcrystalline cellulose in capsules",[19],"Dietary Supplement: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","9g\u002Fday of glycine in capsules",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Microcrystalline cellulose in identifically-looking capsules",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Hong Chang Tan, MD PhD","CONTACT","+65 63214658","tan.hong.chang@singhealth.com.sg",{"type":36,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100614864","dietary-glycine-supplementation-in-metabolic-dysfunction-associated-steatotic-liver-disease-100614864",false,"NCT07285135","Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease","Investigating the Effects of Dietary Glycine Supplementation in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease","Inclusion Criteria:\n\nAll subjects:\n\n1. Age 21-70 years\n2. Ability to provide informed consent.\n\nMASLD group:\n\n1. Hepatic steatosis on MRI\n2. BMI of 25-50 kg\u002Fm2\n\nControls:\n\n1. Absence of hepatic steatosis on MRI\n2. BMI of 18.5-24.9 kg\u002Fm2\n3. No chronic disease\n4. No long-term medications\n\nExclusion Criteria:\n\n1. Uncontrolled diabetes (HbA1c \\> 8%)\n2. Type 1 Diabetes Mellitus\n3. Clinically significant anemia (Haemoglobin \\\u003C 10 g\u002FdL)\n4. Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis\n5. Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)\n6. Glomerular filtration rate (GFR \\\u003C 30 ml\u002Fmin)\n7. Serum alanine transaminase (ALT) \\> 3x upper limit of normal (ULN)\n8. Serum aspartate transaminase (AST) \\> 3x ULN\n9. Liver cirrhosis\n10. Significant alcohol consumption (\\> 20g\u002Fday for women and \\>30g\u002Fday for men)\n11. Receiving weight loss medications or GLP-1 receptor agonists\n12. Pregnancy\n13. Uncontrolled thyroid disease\n14. Previous bariatric surgery\n15. Weight loss \\> 5% in the past 1 month\n16. Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other contraindications to MRI\n17. Claustrophobia\n18. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members)",true,"ALL","21 Years","70 Years",{"count":49,"type":50},60,"ESTIMATED","INTERVENTIONAL",[53],"NA","The purpose of this research study is to determine whether taking glycine, a naturally occurring amino acid, as a supplement improves liver health measurements in individuals with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).\n\nThis project will be divided into two parts. The first part will be a case-control study comparing parameters of glycine-dependent metabolic pathways between individuals with MASLD and healthy controls. The second part will be a randomized placebo-controlled trial (RCT) to evaluate the impact of 26-week dietary glycine supplementation on parameters of liver health versus 26-week placebo in patients with MASLD.",[56],"Metabolic Dysfunction Associated Fatty Liver Disease",[58,59,60],"Fatty liver","Randomized controlled trial","glycine supplements","NOT_YET_RECRUITING","2025-12-02",{"date":64,"type":65},"2025-12-16","ACTUAL",{"date":67,"type":50},"2025-12",{"date":69,"type":50},"2029-01",{"name":5,"class":6}]